Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection Leukemia (2004) Relapse in acute lymphoblastic leukemia (ALL) following hematopoietic stem cell transplant carries an extremely poor prognosis. Relapses of chronic myelogenous leukemia, acute myelogenous leukemia and myelodysplastic syndrome posttransplant have been shown to be responsive to immunologic manipulations such as reductions in immunosuppression and donor lymphocyte infusions. Attempts at similar treatment approaches in ALL have been far less successful and bring into question the efficacy of a graft-versus-leukemia (GVL) effect in this disease. 1 There is, however, considerable evidence that a graft versus leukemia (GVL) effect might exist in ALL. Relapse rates are lower in allogeneic transplants compared with autologous transplants. Similar findings in syngeneic transplants suggest that lack of GVL, rather than tumor contamination, results in an increased rate of relapse in the autologous setting. difficulty in attempting immunologic eradication of lymphoblastic tumor cells may be detecting them at a level before the tumor burden is too high, or the pace of progression is too rapid, to eradicate the leukemia solely through a GVL effect. This limitation could have been overcome if ALL relapse were detected and treated at the point of minimal residual disease (MRD) detection. We report here on 10 cases of ALL posttransplant where immunosuppression was changed after MRD was detected by flow cytometry monitoring. The data suggest a critical threshold of ALL relapse that can be controlled by GVL, and conversely, a level above which GVL has no antileukemic effect.
In all, 10 patients had detectable aberrant lymphoblasts posttransplant by multidimensional flow cytometry (MDF) 5 while still in morphologic remission during routine monitoring, and had a reduction in their immunosuppression in order to facilitate a GVL effect. Detection of aberrant blasts in the marrow by flow cytometry without confirmation by morphology or cytogenetics triggered cell sorting of the abnormal cell population for genotypic confirmation of host origin by chimerism studies. For opposite sex allogeneic transplant patients, X/Y chromosomal fluorescence in situ hybridization (FISH) studies were used. For same sex transplant patients, the donor/host origin of the abnormal cells was determined by variable number of tandem repeat (VNTR) analysis. Changes in immunosuppression and further bone marrow testing were performed at the discretion of the attending physician. All studies were approved by the Institutional Review Board.
In all, 10 patients with residual ALL were identified as having a change in immunosuppression made because of MRD detection. Seven patients had independent confirmation of host origin of the aberrant cells by cell sorting. The remaining three patients had sufficient aberrant lymphoid cells with a phenotype that matched the pretransplant specimen to initiate a change in therapy.
Patient 1 had ALL in 3rd complete remission at the time of transplant. At evaluation on Day þ 80, the patient had finished a prednisone taper for acute gut GVHD and was on cyclosporine A (CsA). On a bone marrow sample, 1.4% abnormal lymphoblasts were found by flow cytometry testing and confirmed to be host genotype. The CsA was rapidly tapered over 7 days, but morphologic relapse occurred 2 weeks later without any worsening of mild skin GVHD.
Patient 2 had refractory Ph þ ALL. The Day þ 28 evaluation revealed 0.2% aberrant lymphoblasts confirmed as host in origin, but due to active skin and gut GVHD, no change was made at that time in the dose of cyclosporine or the 2 mg/kg/day of prednisone therapy administered for GVHD. By Day þ 80, the GVHD had quiesced and only 1 week remained of a prednisone taper when flow cytometry measured 0.1% aberrant cells on a marrow sample. The steroids were immediately discontinued and the CsA rapidly tapered over a 4-week course, but the patient's skin and gut GVHD flared, requiring retreatment with steroids, and later, CsA (2 and 3 months later, respectively). By Day þ 120, the bone marrow was clear of detectable blasts by flow cytometry and morphology. This patient remained in morphologic, as well as flow cytometric, remission as documented by three marrow exams during the next 1 year of followup. All samples post-transplant were tested for the bcr/abl translocation by PCR and showed evidence of minimal residual disease until Day þ 174 when PCR became negative. The patient did well until hematological relapse occurred at 13 months post-transplant. The last bone marrow flow cytometry, morphology and chimerism were obtained 2 months prior (Day þ 318) to relapse and none of these evaluations showed evidence of relapse, although the RT/ PCR assay for bcr/abl was positive.
Patient 3 was transplanted for ALL in 1st persistent relapse. The Day þ 28 evaluation demonstrated 0.2% flow positivity, but morphologic remission. The patient was on prednisone and CsA for acute gut and skin GVHD, so the CsA was decreased to achieve a blood level in the low therapeutic range, and an accelerated steroid taper was started. Subsequently, GVHD flared in response such that prednisone was held at 0.4 mg/kg/ day. By Day þ 75, persistent GVHD activity required the addition of mycophenolate mofetil (MMF)
Patient 5 was transplanted for ALL in 2nd complete remission. The Day þ 80 evaluation revealed 0.2% abnormal cells of host genotype. With only mild acute gut GVHD, the patient's CsA was rapidly tapered over 3 weeks. Severe chronic gut and liver GVHD requiring prolonged hospitalization then developed. A bone marrow evaluation at Day þ 113 showed no abnormal cells. This patient remained in complete remission, but died of severe, refractory gut GVHD on Day þ 199, 4 months following the initially positive marrow sample.
Patient 6 was transplanted for ALL in 1st complete remission. The Day þ 80 evaluation revealed 7.4% abnormal cells of host origin while morphology was reported o5%. The patient had acute gut GVHD and was on CsA and prednisone. With the results of the marrow positivity, CsA was stopped, and a rapid taper of prednisone was begun. Relapse occurred with peripheral blasts just 8 days later.
Patient 7 with ALL in 2nd complete remission was found on Day þ 15 to have 7% peripheral blasts. Flow cytometry on a marrow sample showed 3% abnormal cells. The patient's prophylactic CsA was reduced by Day þ 18 to target a level of 100-150 ng/ml. The Day þ 28 evaluation had only 0.5% abnormal cells by flow cytometry. After 1 week, this was repeated and remained at a similar level of 0.4%. By Day þ 60, the patient relapsed with 70% blasts in the marrow by morphology.
Patient 8 received a reduced-intensity conditioning regimen for lymphoblastic lymphoma in 2nd complete remission. The patient received MMF and CsA for GVHD prophylaxis and was still receiving these agents when the Day þ 28 bone marrow evaluation was performed. Testing revealed adequate engraftment with 98% donor chimerism in the lymphocyte compartment, but the marrow showed 3% abnormal lymphomatous cells of host origin. MMF was therefore discontinued by Day þ 32, but by Day þ 58, morphologic relapse had occurred.
Patient 9 was in 2nd complete remission for ALL with 2.9% flow positivity for aberrant cells on pretransplant testing. The Day þ 28 bone marrow evaluation revealed 0.8% abnormal cells, but, at the physician's discretion, no change in immunosuppression was made. A repeat marrow on Day þ 44 showed 1.5% blasts of host origin, and at this time, the CsA was tapered. With the taper, the patient's GVHD flared. Oral beclomethasone was added to CsA for acute gut symptoms. After 1 month at the Day þ 80 evaluation, a marrow sample revealed no residual blasts by flow cytometry or morphologic inspection. The patient remained in clinical remission, tapering off CsA by Day þ 210, but died of severe refractory bronchiolitis obliterans organizing pneumonia and cytomegalovirus pulmonary infection at 10 months post-transplant.
Patient 10 was an adult with Ph þ ALL in 1st relapse. A pretransplant evaluation noted 20% blasts on bone marrow sampling. Prophylactic CsA was switched to FK506 on Day þ 14 due to a seizure. At Day þ 19, the patient was started on 1 mg/ kg/day of prednisone for acute skin GVHD. The Day þ 34 evaluation noted 3.5% blasts by flow cytometry while still showing morphologic remission. Prednisone was immediately tapered. The next bone marrow sample on Day þ 50 had 0.6% blasts by flow cytometry. A slight flare of skin GVHD occurred, requiring holding the steroids at 0.25 mg/kg/day for one month. By Day þ 78, flow cytometry revealed only 0.3% blasts. PCR was positive for bcr/abl as well. The patient discontinued prednisone on Day þ 95 and started a taper of FK506. On Day þ 140, the patient had a morphologic relapse.
What lessons can be learned from the clinical cases? First, reductions in disease burden were seen in most cases following the reduction of immunosuppression. Six of 10 patients had responses to immunosuppressive tapering (as measured by flow cytometry), consistent with a graft-vs-leukemia effect. This measure was not without cost; two patients (#5 and #9) lost residual disease, but died from GVHD. Another patient (#3) survived GVHD and is now free of disease, 5 years posttransplant. The second point is that the GVL effect was associated with disease burden. No evidence of a GVL effect was seen in the four patients (#1, #4, #6 and #8) with higher disease burden as defined by flow cytometry. These patients relapsed from 8 days to 1 month after detection of abnormal cells, a pace of progression of ALL described in other reports. 5 The burden of minimal residual disease in ALL has been shown to be an important issue in predicting post-transplant relapse. Data obtained using PCR of gene rearrangements showed that detectable pretransplant ALL cells, at levels as low as 0.01%, predicted relapse. 6 Likely, this reflects both the conditioning regimen reducing disease as well as the recipient mounting an immunologic response against the remaining tumor cells. Post-transplant detection of ALL by PCR shows similar results and virtually eliminates the conditioning regimen as a factor. 7 Further evidence for maximizing GVL during minimum tumor burden comes from a report showing reduced prophylactic cyclosporine dosing, in the initial days following transplant (days À1 to þ 10), that led to lower relapse rates in patients with acute leukemias. 8 Consistent with these data, a relation appears between disease burden and relapse in this report ( Figure 1 ). All patients in this small cohort with abnormal blasts detected at levels above 3.5% went on to relapse rapidly by morphologic standards. The patients with lower levels of disease (o1.0%) appear to have had elimination of the blast population following initial detection by MDF.
These data suggest GVL effect may occur in ALL, and is influenced by leukemic burden. Thus, frequent MRD studies might predict relapse such that early detection would allow for various approaches, through reduction in immunosuppression, donor lymphocyte infusions, or adoptive T-cell therapy, which may be ineffective when higher disease burden is present. 
